A statement of changes in beneficial ownership filed on August 13, 2026 discloses that Dermot John Hanley, a director of GH Research PLC, acquired share options on August 11, 2026.

Key Highlights

  • Reporting person: Dermot John Hanley, listed as a Director of GH Research PLC (NASDAQ:GHRS).
  • Transaction date: August 11, 2026, with the filing signed and submitted on August 13, 2026.
  • Securities acquired: 2,202 Share Options (Right to Buy) with an exercise price of $0.025 per share, acquired at a price of $0.
  • Vesting status: According to the filing, the share options are immediately fully vested but are not exercisable until August 11, 2028.
  • Expiration date: The options are set to expire on August 11, 2033, per the filing.
  • Post-transaction ownership: Hanley directly holds 2,202 derivative securities following the reported transaction.

Director Option Grant Details at GH Research PLC

According to the filing, Dermot John Hanley holds a director role at GH Research PLC, an Ireland-based company headquartered at Joshua Dawson House, Dawson Street, Dublin. The transaction code recorded is "A," indicating an acquisition of derivative securities rather than a disposal.

The filing discloses that 2,202 Share Options (Right to Buy) were acquired on August 11, 2026, with each option carrying an exercise price of $0.025 and an underlying security of Ordinary Shares of GH Research PLC. The filing notes that the options were acquired at a price of $0 and that, although they are immediately fully vested, they remain non-exercisable until August 11, 2028. The options are set to expire on August 11, 2033. Following this transaction, Hanley is reported to directly and beneficially own 2,202 derivative securities in total.

No transactions were reported in Table I covering non-derivative securities, meaning the filing contains no record of direct acquisitions or disposals of Ordinary Shares by Hanley during the reported period. The filing was submitted as an individual filing by one reporting person and does not indicate any amendment to a previously filed form.

What Was Disclosed

The filing reports the acquisition of 2,202 Share Options (Right to Buy) by GH Research PLC director Dermot John Hanley on August 11, 2026, at no cost, with an exercise price of $0.025, fully vested but not exercisable before August 11, 2028.